Expanding NAD Category And Clinical Pipeline Will Drive Powerful Long-Term Upside

Catalysts

About Niagen Bioscience

Niagen Bioscience develops and commercializes scientifically validated NAD boosting ingredients and products that promote healthy aging across consumer, clinical and potential pharmaceutical applications.

What are the underlying business or industry changes driving this perspective?

• Rapid expansion of the NAD category, coupled with Niagen's position as a clinically validated and differentiated NAD precursor, is cited by some observers as supporting sustained premium pricing and continued revenue growth as awareness accelerates.
• Scaling e-commerce and practitioner-led distribution, including access to over 8,000 medical and health care practitioners and more than 1,000 wellness clinics, is expected to deepen brand penetration, increase repeat purchases and potentially improve leverage in selling and marketing expense as a percentage of net sales.
• Development of Niagen Plus injectable and at-home kits, alongside growing telehealth and GLP-1 usage, is intended to open a new, higher ticket therapy channel that could expand average revenue per customer and support structurally higher gross margins.
• Advancing clinical programs in Parkinson's disease, ataxia-telangiectasia and long COVID, together with ongoing discussions with pharmaceutical partners and a potential dedicated Rx entity, may create optionality for licensing, milestone income and changes in earnings power.
• A strengthening financial profile with improving profitability, gross margins, disciplined operating expenses and a debt free balance sheet with $64.3 million in cash is described as positioning the company to invest in growth while working to expand net margins and earnings per share.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on Niagen Bioscience compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming Niagen Bioscience's revenue will grow by 19.9% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 14.3% today to 18.1% in 3 years time.
• The bullish analysts expect earnings to reach $40.7 million (and earnings per share of $0.47) by about July 2029, up from $18.6 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $25.7 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 51.1x on those 2029 earnings, up from 14.1x today. This future PE is greater than the current PE for the US Personal Products industry at 15.9x.
• The bullish analysts expect the number of shares outstanding to decline by 0.14% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.2%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Intensifying competition in the NAD booster market, including expanding NMN supply despite regulatory ambiguity and potential patent infringement, could erode Niagen's ability to sustain premium pricing and share gains over time. This would pressure revenue growth and compress net margins.
• The clinic, IV and at-home injection opportunity may remain a high priced niche if partners and providers are slow to lower pricing or adopt Niagen Plus broadly. This would delay the ramp in patient volumes and telehealth uptake that management is counting on, which would limit incremental revenue and reduce the operating leverage assumed in future earnings.
• Rising operating expenses driven by higher share based compensation, increased G&A and ongoing R&D investment could outpace revenue growth as the company scales. This would cap improvements in profitability and constrain the expansion of net income and earnings per share.
• Regulatory and legal risks, including potential reversals of FDA positions on competing NAD precursors and enforcement or challenges around Niagen's own patent estate, may alter the competitive playing field or require costly litigation. This would create volatility in ingredient demand and weigh on earnings.
• Clinical and pharmaceutical optionality in areas like Parkinson's disease, ataxia telangiectasia and long COVID may not translate into positive trial readouts, regulatory approvals or attractive pharma partnerships on a reasonable timeline. This would significantly reduce the upside embedded in long term revenue, high margin licensing income and future earnings power.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Niagen Bioscience is $21.2, which represents up to two standard deviations above the consensus price target of $12.5. This valuation is based on what can be assumed as the expectations of Niagen Bioscience's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $22.0, and the most bearish reporting a price target of just $9.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $224.6 million, earnings will come to $40.7 million, and it would be trading on a PE ratio of 51.1x, assuming you use a discount rate of 7.2%.
• Given the current share price of $3.3, the analyst price target of $21.2 is 84.4% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.